Limits...
One Year Outcomes of Photorefractive Keratectomy with the Application of Mitomycin-C in the Treatment of Mild to Moderate Hyperopia.

Habibollahi A, Hashemi H, Seyedian MA, Mehravaran S, Asgari S, Habibollahi S, Habibollahi S, Khabazkhoob M - Middle East Afr J Ophthalmol (2015 Oct-Dec)

Bottom Line: BCVA increased by two lines or more in three eyes (7.1%) and one line in two eyes (4.7%); 31 eyes showed no change, three eyes (7.1%) lost one line, and three other eyes (7.1%) lost two lines of BCVA.No eyes lost more than two lines of BCVA.Complications included Grade 2 peripheral haze in two eyes which cleared by 12 months postoperatively.

View Article: PubMed Central - PubMed

Affiliation: Noor Ophthalmology Research Center, Noor Eye Hospital, Tehran, Iran.

ABSTRACT

Purpose: To evaluate refractive and visual outcomes of photorefractive keratectomy with mitomycin-C. (PRK-MMC) for the treatment of mild to moderate hyperopia.

Materials and methods: This case series enrolled 21 patients with up to +5.50 diopters (D) of hyperopia. All 42 eyes were treated with the Concerto (Wavelight) or the Technolas 217-Z (Bausch and Lomb) excimer laser. Outcome measures included best corrected distance vision acuity (BCVA) and uncorrected distance vision correction and refraction at 1, 3, 6, and 12 months postoperatively.

Results: Mean patient age was 44.8 ± 11.3 years. Preoperatively, mean manifest refractive spherical equivalent (MRSE) was + 2.00 D ± 0.76 D and mean spherical refractive error was + 2.57 D ± 0.87 D (range, +1.25 D to + 5.50 D). At 12 months postoperatively, mean MRSE was + 0.1 D ± 0.61 D. MRSE was within ± 0.50 D of emmetropia in 29 eyes (69%), and 18 eyes (43%) had 20/20 uncorrected distant visual acuity. BCVA increased by two lines or more in three eyes (7.1%) and one line in two eyes (4.7%); 31 eyes showed no change, three eyes (7.1%) lost one line, and three other eyes (7.1%) lost two lines of BCVA. No eyes lost more than two lines of BCVA. Complications included Grade 2 peripheral haze in two eyes which cleared by 12 months postoperatively.

Conclusion: PRK-MMC was a safe and predictable method for the correction of mild to moderate hyperopia.

Show MeSH

Related in: MedlinePlus

Safety of hyperopic photorefractive keratectomy with mitomycin-C at 12 months postoperatively. Thirty-one eyes showed no change, two lost two lines, and two gained two lines
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4660537&req=5

Figure 3: Safety of hyperopic photorefractive keratectomy with mitomycin-C at 12 months postoperatively. Thirty-one eyes showed no change, two lost two lines, and two gained two lines

Mentions: At 12 months postoperatively, both spherical error and MRSE were significantly different from the preoperative values (P < 0.001); 69.0% were within ± 0.50 D, and 98.0% were within ± 1.00 D of emmetropia. At this time, 18 eyes (42.9%) had UCVA of 20/20, and in 39 eyes (92.8%) UCVA was 20/40 or better. The best spectacle-corrected distance visual acuity (BCVA) increased by two lines in three eyes (7.1%) and one line in two eyes (4.7%), 31 eyes (73.8%) showed no change, three eyes (7.1%) lost one line, and three other eyes (7.1%) lost two lines of corrected vision [Figure 3].


One Year Outcomes of Photorefractive Keratectomy with the Application of Mitomycin-C in the Treatment of Mild to Moderate Hyperopia.

Habibollahi A, Hashemi H, Seyedian MA, Mehravaran S, Asgari S, Habibollahi S, Habibollahi S, Khabazkhoob M - Middle East Afr J Ophthalmol (2015 Oct-Dec)

Safety of hyperopic photorefractive keratectomy with mitomycin-C at 12 months postoperatively. Thirty-one eyes showed no change, two lost two lines, and two gained two lines
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4660537&req=5

Figure 3: Safety of hyperopic photorefractive keratectomy with mitomycin-C at 12 months postoperatively. Thirty-one eyes showed no change, two lost two lines, and two gained two lines
Mentions: At 12 months postoperatively, both spherical error and MRSE were significantly different from the preoperative values (P < 0.001); 69.0% were within ± 0.50 D, and 98.0% were within ± 1.00 D of emmetropia. At this time, 18 eyes (42.9%) had UCVA of 20/20, and in 39 eyes (92.8%) UCVA was 20/40 or better. The best spectacle-corrected distance visual acuity (BCVA) increased by two lines in three eyes (7.1%) and one line in two eyes (4.7%), 31 eyes (73.8%) showed no change, three eyes (7.1%) lost one line, and three other eyes (7.1%) lost two lines of corrected vision [Figure 3].

Bottom Line: BCVA increased by two lines or more in three eyes (7.1%) and one line in two eyes (4.7%); 31 eyes showed no change, three eyes (7.1%) lost one line, and three other eyes (7.1%) lost two lines of BCVA.No eyes lost more than two lines of BCVA.Complications included Grade 2 peripheral haze in two eyes which cleared by 12 months postoperatively.

View Article: PubMed Central - PubMed

Affiliation: Noor Ophthalmology Research Center, Noor Eye Hospital, Tehran, Iran.

ABSTRACT

Purpose: To evaluate refractive and visual outcomes of photorefractive keratectomy with mitomycin-C. (PRK-MMC) for the treatment of mild to moderate hyperopia.

Materials and methods: This case series enrolled 21 patients with up to +5.50 diopters (D) of hyperopia. All 42 eyes were treated with the Concerto (Wavelight) or the Technolas 217-Z (Bausch and Lomb) excimer laser. Outcome measures included best corrected distance vision acuity (BCVA) and uncorrected distance vision correction and refraction at 1, 3, 6, and 12 months postoperatively.

Results: Mean patient age was 44.8 ± 11.3 years. Preoperatively, mean manifest refractive spherical equivalent (MRSE) was + 2.00 D ± 0.76 D and mean spherical refractive error was + 2.57 D ± 0.87 D (range, +1.25 D to + 5.50 D). At 12 months postoperatively, mean MRSE was + 0.1 D ± 0.61 D. MRSE was within ± 0.50 D of emmetropia in 29 eyes (69%), and 18 eyes (43%) had 20/20 uncorrected distant visual acuity. BCVA increased by two lines or more in three eyes (7.1%) and one line in two eyes (4.7%); 31 eyes showed no change, three eyes (7.1%) lost one line, and three other eyes (7.1%) lost two lines of BCVA. No eyes lost more than two lines of BCVA. Complications included Grade 2 peripheral haze in two eyes which cleared by 12 months postoperatively.

Conclusion: PRK-MMC was a safe and predictable method for the correction of mild to moderate hyperopia.

Show MeSH
Related in: MedlinePlus